Stay updated on Nivolumab Alone or Combined With Ipilimumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Alone or Combined With Ipilimumab in Solid Tumors Clinical Trial page.
Latest updates to the Nivolumab Alone or Combined With Ipilimumab in Solid Tumors Clinical Trial page
- Check2 days agoChange DetectedRevision tag updated to v3.3.4, replacing the previous v3.3.3. This change is limited to internal version labeling and does not alter study details or page content; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%
- Check10 days agoChange DetectedThe CheckMate-032 publication citation in Publications From PubMed was updated: the erratum version is now listed, replacing the original citation.SummaryDifference0.0%
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe page's Locations section now adds multiple new study sites, including Alabama, Colorado, Connecticut, Florida, Georgia, Maryland, Massachusetts, Nebraska, New York, North Carolina, Oregon, Tennessee, Texas, Washington, Ontario, Uusimaa, Greater London, Lanarkshire, and Surrey. Several locations were removed, altering where the study is recruiting.SummaryDifference2%
- Check53 days agoChange DetectedAdded a note clarifying that publications shown are automatically filled from PubMed and may not be about the study; updated the revision label to v3.3.2 and adjusted the corresponding deletion note to v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check60 days agoChange DetectedThe government funding notice about potential data delays and NIH Clinical Center status has been removed; it previously warned that information might not be up to date and directed readers to cc.nih.gov and opm.gov for status updates.SummaryDifference0.3%
- Check74 days agoChange DetectedThe changes seem to be cosmetic UI/formatting adjustments with no alteration of core trial information (such as eligibility criteria, interventions, outcomes, or status). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%
Stay in the know with updates to Nivolumab Alone or Combined With Ipilimumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Alone or Combined With Ipilimumab in Solid Tumors Clinical Trial page.